Early increase in anti-inflammatory biomarkers is associated with the development of multiple organ dysfunction syndrome in severely injured trauma patients

Derek JB Kleinveld,1,2 Anita M Tuip-de Boer,1 Markus W Hollmann,1,3 Nicole P Juffermans1,2

ABSTRACT

Background As a result of improvements in the early resuscitation phase of trauma, mortality is largely driven by later mortality due to multiple organ dysfunction syndrome (MODS), which may be mediated by an early overdrive in the host immune response. If patients at risk for MODS could be identified early, preventive treatment measures could be taken. The aim of this study is to investigate whether specific biomarkers are associated with MODS.

Methods Multiple trauma patients presenting to the Amsterdam University Medical Centers, Academic Medical Center, between 2012 and 2018 with an Injury Severity Score of 16 or higher were sampled on arrival at the emergency department. A wide variety of inflammatory cytokines, endothelial and lung-specific markers were determined. Comparisons were made between patients with and without MODS. Univariate and multivariate logistic regression was used to determine associations between specific biomarkers and MODS. A p value of 0.05 was considered to be statistically significant.

Results In total, 147 multiple trauma patients were included. Of these, 32 patients developed MODS (21.7%). Patients who developed MODS were more severely injured, had more traumatic brain injury and showed more deranged markers of coagulation when compared with patients without MODS. Overall, both proinflammatory and anti-inflammatory cytokines were higher in patients with MODS, indicative of a host immune reaction. In the multivariate analysis, the combination of anti-inflammatory proteins interleukin 1 receptor antagonist (IL-1RA) (OR 1.27 (1.07–1.51), p=0.002) and Clara cell protein 16 (CC-16) (1.06 (1.01–1.05), p=0.031) was most strongly associated with the development MODS.

Conclusions In trauma, anti-inflammatory proteins IL-1RA and CC-16 have the potential to early identify patients at risk for development of MODS. Further research is warranted to prospectively validate these results.

Level of evidence Prognostic study, level III.

BACKGROUND

Improvements in the management of major bleeding have led to shifts in morbidity and mortality towards later stages in the course of trauma.12 These improvements in early trauma survival result in an increase in patients prone to develop inflammatory complications later in time, such as acute respiratory distress syndrome (ARDS), acute kidney injury (AKI) and multiple organ dysfunction syndrome (MODS).1 3–7 These complications all contribute to late mortality, which is around 20% to 30% in multiple trauma patients.1 2 It is hypothesized that the development of organ failure is mediated by an augmented immune response to damage-associated molecular patterns, which are released from tissues in large amounts after trauma, leading to MODS.3–12 Multiple different pathways, including inflammation, coagulation and endothelial activation, are involved in the progression of MODS.3–14 Previous studies using biomarkers to predict ARDS in trauma have shown that both epithelial and endothelial markers are involved.13 14 For example, Clara cell protein 16 (CC-16), which is an anti-inflammatory pulmonary secretory protein,17 18 and angiotensin-2, a marker of endothelial activation, were increased in patients with ARDS compared with patients without ARDS.16 Other markers of endothelial activation include thrombomodulin-1 and syndecan-1, which are increased in patients developing MODS already prior to hospital arrival.16 Moreover, a study evaluating biomarkers in the progression of AKI after trauma showed an early increase in interleukin 1 receptor antagonist (IL-1RA), indicating an upregulation in blocking of interleukin 1 pathways.16 Another study evaluating the prehospital immune response showed potential relationships between both immune activation and suppression in patients with MODS, underlining the multifactorial process.20 Additionally, evaluation of immune cell genes revealed a specific upregulation of pathways associated with cell death and a hyperacute innate immune response.11

Currently, however, it is unclear which markers from these different inflammatory pathways, endothelial activation pathways and/or lung-specific damage markers are most strongly correlated with the development of organ failure.21–23 If early measured biomarkers are associated with MODS, early targeted treatment strategies could be initiated.

The aim of this study was to identify biomarkers of inflammation, endothelial activation and markers related to lung-specific damage early in the course
of trauma and investigate which of these biomarkers were most strongly associated with the development of MODS.

METHODS

Study participants
This cross-sectional study was conducted as a substudy of the observational prospective cohort study ‘Activation of Coagulation and Inflammation in Trauma-3 (ACIT-3)’.24

Patients from 2012 to 2018 admitted to the level 1 trauma unit were eligible for inclusion. Inclusion criteria were adult (18 years or older) patients suffering from blunt or penetrating trauma with vital signs indicative of shock (e.g., heart rate of 120 bpm or more, systolic blood pressure of 90 mmHg or less, or estimated blood loss >500 mL) or suspicion of one of the following clinical diagnoses: femur fracture, multiple rib fractures, pneumothorax, severe abdominal injury or pelvic fractures. Exclusion criteria were transfer from another hospital, presentation longer than 120 minutes after trauma, receipt of more than 2000 mL of crystalloids infusion prior to admission, burn injury of more than 5% of their body surface, use of anti-coagulant medication, known bleeding diathesis or known liver disease (Child-Pugh classification B or C).

Baseline hemodynamic vital variables were recorded. Traumatic brain injury (TBI) was scored as a head abbreviated Injury Severity Score (ISS) of 3 or more. Blood gas analysis and laboratory tests were assessed.

In this substudy, patients who had an injury severity (ISS) of 16 or higher were selected. Patients were further subdivided into patients with and without MODS.

Outcome parameters
ARDS was diagnosed according to the Berlin criteria.25–27 Patients with AKI stage I, II or III, as determined using the RIFLE criteria (acronym for Risk of renal dysfunction, Injury to the kidney, Failure of kidney function, Loss of kidney function and End-stage kidney disease), were scored.28–29 MODS was defined by sequential organ failure assessment score of 3 or higher in two or more organ systems, scored from 48 hours after trauma onwards. Furthermore, ventilator-days, intensive care stay, total length of stay in hospital and early (24 hours) and late mortality (30 days) were recorded.

Laboratory analysis of biomarkers
Whole blood was collected in EDTA tubes at trauma presentation in the emergency department (ED). Plasma was prepared with a single centrifugation step (1750G, 10 minutes, 18°C, Eppendorf 5804K). The upper two-thirds of the plasma was collected and stored at −80°C for later analysis. Plasma samples were assessed using a multianalyte luminescent kit (R&D Systems, Minneapolis, USA), consisting of the following biomarkers: myeloperoxidase (MPO), tumor necrosis factor-α (TNF-α), TNF-α receptor 1 and 2 (TNF-R1 and TNF-R2), interleukin 6 (IL-6), interleukin 8 (IL-8), receptor for advanced glycation end-products (RAGE), first apoptosis signal (FAS) ligand, surfactant protein D (SP-D), Krebs von den Lungen-6 (KL-6), IL-1RA, interleukin 10 (IL-10), macrophage migration inhibitory factor-1α (MIF-1α), CC-16, E-selectin, tissue factor (TF), intercellular adhesion molecule 1 (ICAM-1), vascular cellular adhesion molecule 1 (VCAM-1) and plasminogen antigen inhibitor 1 (PAI-1). This panel was chosen based on previous literature on inflammation,19 20 31 endotheliopathy14 and lung-specific complications16 in trauma.

Statistical analysis
Statistical analysis was done using SPSS Statistics V.25 (IBM), graphs were made employing PRISM V.8 (GraphPad, California, USA). Values of biomarkers below the detection value were rated as half of the lowest detectable value.12

Normality was checked using Kolmogorov-Smirnov test and visual assessment of histograms. For normal distributed data, Student’s t-test was used, and a Mann-Whitney U test was used for non-parametric data. χ² test or Fisher’s exact test was used to detect differences between proportions.

After assessing the association between potential biomarkers and MODS, a univariate logistic regression was made using each biomarker independently. Biomarkers with p value <0.10 were further evaluated in the multivariate regression analysis using forward selection. A maximum of three association measures was used in the final multivariate regression analysis.33

Receiver operating curves were made to visualize the potential sensitivity and specificity of biomarkers. The combined estimate was calculated using the estimate calculation from the multivariate regression analysis. A p value <0.05 was considered to be statistically significant.

RESULTS

Baseline characteristics
In total, 189 patients with an ISS of 16 or higher were included in ACIT trial between 2012 and 2018. Of the 189 patients, 42 were retrospectively excluded in this substudy based on: no informed consent obtained (n=33), anticoagulant medication use (n=4), time from hospital to admission longer than 2 hours (n=3), and burn injury of more than 5% of body surface (n=2). The baseline characteristics of the included patients (n=147) are shown in table 1. 21.7% of patients developed MODS, with a median time to development of 3 days. The most prevalent complication was AKI (13.6%) followed by ARDS (6.8%). Patients with MODS had significantly higher ISS compared with patients without MODS, more often had brain injury, had a higher base deficit on arrival and had more deranged coagulation parameters. As expected, patients with MODS had longer intensive care unit and hospital stay than patients without MODS. As patients need to survive the initial hit of trauma, early mortality occurred only in patients without MODS and was related either to TBI (80.0%) or exsanguination (20.0%). Reasons for late mortality included severe TBI (58.3%), severe organ failure (25.0%), circulatory collapse (8.3%) and psychiatric condition leading to suicide (8.3%). In patients who survived the first 24 hours but died within 30 days, mortality occurred after a median of 7.5 days.

Biomarkers are associated with multiple organ failure
Patients who developed MODS had significantly higher baseline levels of proinflammatory cytokines (IL-6, IL-8, TNF-R1, FAS ligand, RAGE and MPO) than patients without MODS. Also, higher levels of baseline IL-1RA were seen in patients with MODS compared with patients without MODS, more often had brain injury, had a higher base deficit on arrival and had more deranged coagulation parameters. As expected, patients with MODS had longer intensive care unit and hospital stay than patients without MODS. As patients need to survive the initial hit of trauma, early mortality occurred only in patients without MODS and was related either to TBI (80.0%) or exsanguination (20.0%). Reasons for late mortality included severe TBI (58.3%), severe organ failure (25.0%), circulatory collapse (8.3%) and psychiatric condition leading to suicide (8.3%). In patients who survived the first 24 hours but died within 30 days, mortality occurred after a median of 7.5 days.
Table 1  Baseline characteristics

| Parameter | All patients (n=147) | No MODS (n=115) | MODS (n=32) | P value |
|-----------|---------------------|-----------------|-------------|---------|
| Demographics |                     |                 |             |         |
| Age (years) | 53 (31–64)         | 53 (35–64)      | 50 (28–68)  | 0.959   |
| Female sex, n (%) | 40 (27.2)          | 25 (21.7)       | 15 (46.9)   | 0.005   |
| Blunt injury, n (%) | 141 (95.9)         | 110 (95.7)      | 31 (96.9)   | 0.757   |
| Injury Severity Score | 22 (17–29)          | 20 (17–27)      | 25 (22–30)  | 0.010   |
| TBI, n (%) | 88 (59.9)           | 64 (55.7)       | 24 (75.0)   | 0.048   |
| Laboratory parameters |                 |                 |             |         |
| pH | 7.37 (7.32–7.41) | 7.38 (7.33–7.41) | 7.34 (7.26–7.38) | 0.002 |
| PaCO₂ (mm Hg) | 42.8 (26.8–48.0) | 42.8 (36.0–48.0) | 45.4 (39.6–49.9) | 0.094 |
| P/F ratio (mm Hg) | 315.0 (172.5–442.9) | 333.8 (173.1–461.1) | 220.5 (147.5–351.0) | 0.069 |
| Lactate (mmol/L) | 2.1 (1.3–3.0) | 2.0 (1.3–3.0) | 2.2 (1.4–3.1) | 0.917 |
| BE | −1.5 (−3.6 to 0.5) | −1.2 (−3.1 to 0.8) | −2.7 (−6.1 to −0.6) | 0.005 |
| Leukocytes (×10⁹/L) | 10.8 (7.9–15.1) | 11.1 (8.1–15.0) | 10.2 (7.2–15.7) | 0.555 |
| Hb (g/dL) | 12.5 (8.9–13.8) | 12.8 (9.8–14.0) | 9.6 (7.0–12.5) | <0.001 |
| Creatinine (µmol/L) | 73.0 (62.0–90.3) | 73.0 (62.0–90.3) | 70 (61.3–92.0) | 0.913 |
| ALT (U/L) | 31.0 (21.0–64.0) | 31.5 (22.0–63.3) | 28.0 (18.0–71.0) | 0.733 |
| Coagulation |                     |                 |             |         |
| Platelet count (×10⁹/L) | 217.5 (58.3) | 220.6 (57.6) | 203.0 (60.7) | 0.690 |
| PT (s) | 11.8 (11.3–12.6) | 11.7 (11.3–12.4) | 12.7 (11.7–14.7) | 0.001 |
| aPTT (s) | 24.0 (22.0–26.0) | 24.0 (22.0–26.0) | 25.0 (23.0–28.0) | 0.008 |
| Fibrinogen (g/L) | 2.2 (0.7) | 2.3 (0.7) | 1.8 (0.6) | 0.003 |
| D-dimer (mg/L) | 10.3 (3.5–32.0) | 9.4 (3.3–32.0) | 14.3 (5.1–30.0) | 0.515 |
| Outcomes |                     |                 |             |         |
| Ventilation (days) | 1 (0–4) | 0 (0–1) | 10 (4–16) | <0.001 |
| ARDS, n (%) | 10 (6.8) | 1 (0.9) | 9 (28.1) | <0.001 |
| AKI, n (%) | 20 (13.6) | 4 (3.5) | 16 (50.0) | <0.001 |
| MODS, n (%) | 32 (21.8) | 0 (0) | 32 (100) | ND |
| With ARDS | 9/32 | 0 | 9/32 | ND |
| With AKI | 16/32 | 0 | 16/32 | ND |
| With ARDS and AKI | 6/32 | 0 | 6/32 | ND |
| Length of ICU stay (days) | 2 (1–5) | 1 (0–3) | 13 (6–19) | <0.001 |
| Total length of stay (days) | 8 (5–19) | 7 (4–15) | 24 (13–35) | <0.001 |
| 24-hour mortality, n (%) | 10 (6.8) | 10 (8.7) | 0 (0) | 0.119 |
| 24-hour to 28-day mortality, n (%) | 12 (8.2) | 3 (2.6) | 9 (28.1) | <0.001 |

Data are represented as number (percentage), median (IQR) or mean (SD). MODS was defined as a sequential organ failure assessment (SOFA) score of 3 or more in two or more organ systems. TBI was defined as an abbreviated head injury score of 3 or higher. Comparisons were made between patients with and without MODS.

AKI, acute kidney injury; ALT, alanine amino transferase; aPTT, activated partial thromboplastin time; ARDS, acute respiratory distress syndrome; BE, base excess; FiO₂, fractional inspired oxygen; Hb, hemoglobin; ICU, intensive care unit; MODS, multiple organ dysfunction syndrome; ND, not determined; PaCO₂, partial pressure of carbon dioxide; PaO₂, partial arterial oxygen pressure; P/F, PaO₂/FiO₂; PT, prothrombin time; TBI, traumatic brain injury.

**DISCUSSION**

The aim of this study was to examine the potential prognostic properties of plasma biomarkers to identify patients at risk for development of MODS after trauma. In this cohort of severely injured patients, 21.7% developed MODS. An early increase in anti-inflammatory proteins IL-1RA and CC-16 at presentation to the ED was associated with the development of MODS after 3 days, which was independent of the ISS.

In this study, proinflammatory cytokines were higher in patients with MODS compared with patients without MODS, but these were not independently associated with development of MODS. The strongest association was found with the anti-inflammatory biomarker IL-1RA. Previous studies have shown a profound immune cell activation in trauma with components of activation and suppression, occurring already at ED presentation. This suppression of immune cells after trauma, depicted by lower cytokine production, was also present in this cohort. Previously, we showed that the ex vivo ability of these trauma patients to generate an immune response to lipopolysaccharide stimulation was impaired when compared with healthy volunteers. Additionally, trauma patients have lower expressions of monocyte toll-like receptors compared to healthy volunteers. Furthermore, underlying these results, a study performed in 166 polytrauma patients revealed a similar pattern of early IL-10 release and a decrease in human leukocyte antigen—DR isotype expression, potentially reducing macrophage functions. Additionally, although based on a small number of patients (n=44), major trauma was associated with an impairment of neutrophil
Patients. In a study of 101 polytrauma patients with severe chest trauma, higher levels of CC-16 were found at admission and day 2 in patients who developed pneumonia compared with patients without pneumonia. Furthermore, patients with ARDS from multiple causes including trauma showed higher levels of CC-16 compared with patients without ARDS. In this study, mice were treated with anti-CC-16 antibodies or IgG directly after trauma. Early anti-CC-16 treatment was associated with more neutrophil infiltration and more damaged lung tissue compared with IgG vehicle-treated mice. Taken together, in the present study MODS seemed more related to anti-inflammatory proteins than to proinflammatory proteins. It remains to be determined how these cytokines contribute to organ failure after trauma, as their function is thought to be inhibition of the inflammatory response to prevent further tissue damage. We speculate that an overshoot in inflammation causes an overshoot in anti-inflammatory proteins. Alternatively, IL-1RA in trauma may exert more functions than inhibition of IL-1, in a fashion which is as yet undetermined.

Remarkably, markers of endothelial dysfunction did not differ between patients with and without MODS. Both groups had elevated VCAM-1 and ICAM-1 levels at presentation, indicative of endothelial barrier dysfunction, which is in line with previous literature. However, the finding that patients with MODS did not exhibit more endothelial dysfunction at presentation is in contrast with previous findings. These studies showed persistent function. Interestingly, in mice with TBI and tibia fracture receiving IL-1RA treatment, a decrease in neutrophil activation markers and cerebral edema was seen. The exact mechanism of immune paralysis directly after trauma is poorly understood. Our results suggest that IL-1RA might play a role in the progression of MODS.

In line with this, we found that CC-16 levels in patients with MODS were higher compared with patients without MODS. CC-16 is also an anti-inflammatory protein and suggested as biomarker for the development of pneumonia in trauma patients. In a study of 101 polytrauma patients with severe chest trauma, higher levels of CC-16 were found at admission and day 2 in patients who developed pneumonia compared with patients without pneumonia. Furthermore, patients with ARDS from multiple causes including trauma showed higher levels of CC-16 compared with patients without ARDS. In this study, 28.1% of patients with MODS also fulfilled the ARDS criteria, which could partly explain the association of CC-16 with the development of MODS in this study. The anti-inflammatory effects of CC-16 in the present study MODS seemed more related to anti-inflammatory proteins than to proinflammatory proteins. It remains to be determined how these cytokines contribute to organ failure after trauma, as their function is thought to be inhibition of the inflammatory response to prevent further tissue damage. We speculate that an overshoot in inflammation causes an overshoot in anti-inflammatory proteins. Alternatively, IL-1RA in trauma may exert more functions than inhibition of IL-1, in a fashion which is as yet undetermined.

*Data are represented as median with IQR. Comparisons are made between patients with and without MODS.

**p<0.05; ***p<0.01; ****p<0.001.

Table 2

| Biomarkers | All patients (n=147) | No MODS (n=115) | MODS (n=32) |
|------------|----------------------|-----------------|-------------|
| MPO (ng/mL)| 29.3 (20.2–44.7)     | 25.8 (18.2–41.7)| 35.7 (26.2–58.8)*** |
| TNF-α (pg/mL)| 6.9 (1.7–13.4)       | 7.9 (1.7–13.2) | 1.7 (1.7–14.6) |
| TNF-R1 (pg/mL)| 1766.4 (1292.4–2460.4) | 1627.1 (1218.0–2288.7) | 2280.1 (1631.9–3427.1)*** |
| TNF-RII (pg/mL)| 1665.0 (1226.8–2340.3) | 1628.3 (1203.4–2309.7) | 1841.1 (1314.4–3058.9) |
| IL-6 (pg/mL)| 23.2 (13.6–60.4)     | 21.8 (11.2–45.5) | 39.8 (21.4–108.2)*** |
| IL-8 (pg/mL)| 8.9 (5.8–15.6)       | 8.5 (5.4–13.0)  | 11.6 (8.0–24.8)*** |
| RAGE (pg/mL)| 1844.4 (1242.5–3423.0) | 1670.3 (1151.3–3408.9) | 2302.2 (1677.8–3439.9)* |
| FAS ligand (pg/mL)| 54.7 (36.0–68.9) | 51.5 (31.6–67.3) | 58.1 (48.5–83.3)* |
| SP-D (ng/mL)| 9.1 (5.8–13.4)       | 9.3 (6.5–13.1)  | 7.2 (5.2–14.0) |
| KL-6 (pg/mL)| 18.9 (10.7–26.6)     | 19.3 (11.0–27.0) | 17.2 (10.4–25.6) |
| IL-1RA (pg/mL)| 861.8 (603.3–1394.4) | 774.6 (569.9–1277.7) | 1284.6 (777.2–2911.2)*** |
| IL-10 (pg/mL)| 19.4 (8.8–48.7)      | 18.9 (8.8–46.6) | 32.7 (8.8–50.3) |
| MIF-1α (pg/mL)| 228.5 (143.7–266.4) | 228.5 (141.8–264.4) | 233.2 (158.0–288.9) |
| CC-16 (ng/mL)| 14.0 (8.0–25.7)      | 12.3 (7.4–21.4) | 25.0 (14.1–44.1)*** |
| E-selectin (ng/mL)| 16.6 (12.9–22.2) | 17.5 (13.0–22.8) | 16.2 (11.1–19.5) |
| TF (pg/mL)| 30.7 (24.1–37.8)     | 30.5 (24.1–37.8) | 31.3 (23.9–38.2) |
| ICAM-1 (ng/mL)| 225.1 (162.4–324.8) | 233.4 (162.4–324.8) | 206.9 (159.5–336.1) |
| VCAM-1 (ng/mL)| 769.1 (571.9–984.6) | 769.1 (578.0–992.3) | 776.8 (558.9–939.0) |
| FAS ligand (pg/mL)| 7.2 (5.2–14.0) | 6.9 (1.7–13.4) | 7.9 (1.7–13.2) |

Table 3

| Parameter | Univariate model OR (95% CI) | P value | Multivariate model OR (95% CI) | P value |
|-----------|-----------------------------|---------|-------------------------------|---------|
| ISS       | 1.04 (1.00 to 1.08)         | 0.040   | ND                            | 0.482   |
| IL-1RA (ng/mL)| 1.27 (1.07 to 1.51)      | 0.001   | 1.22 (1.02 to 1.47)           | 0.002   |
| CC-16 (ng/mL)| 1.03 (1.01 to 1.05)       | 0.001   | 1.03 (1.01 to 1.05)           | 0.031   |

Multivariate logistic regression model with forward selection to a maximum of three variables.

MODS was defined as a sequential organ failure assessment (SOFA) score of 3 or more in two or more organ systems.

CC-16, Clara cell protein 16; IL-1RA, interleukin 1 receptor antagonist; ISS, Injury Severity Score; MODS, multiple organ dysfunction syndrome; ND, not determined.
For injury severity, which is associated with many of these parameters, higher syndecan-1 and thrombomodulin levels in patients who developed MODS. An explanation for this result could be that endothelial barrier function was measured with different biomarkers in this study (e.g., TF, ICAM-1, VCAM-1), which might increase later in the course of trauma than markers of glycocalyx degradation (e.g., syndecan-1 and thrombomodulin). Alternatively, differences between the timing of measurement of biomarkers may have played a role.

This study has several limitations. Patients with MODS differed from patients not developing MODS. They were more often female and more often had TBI compared with patients without MODS. Also, these patients had higher base deficits without MODS. Also, these patients had higher base deficits and more often had TBI compared with patients without MODS. Furthermore, the mechanisms by which anti-inflammatory pathways contribute to trauma-related MODS should be further studied.

**Contributors** DIBK drafted the article, performed luminex and statistical analysis, and revised all versions of the article. AMTB performed luminex analysis. MWH supervised the project. NPJ supervised the project, and revised all versions of the article. All authors approved the final article.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not required.
multiple organ dysfunction syndrome following traumatic injury: a prospective cohort study. *PloS Med* 2017;14:e1002338.

21 Fang Y, Li C, Shao R, Yu H, Zhang Q. The role of biomarkers of endothelial activation in predicting morbidity and mortality in patients with severe sepsis and septic shock in intensive care: a prospective observational study. *Thromb Res* 2018;171:149–54.

22 Parlato M, Philipart F, Rouquetta A, Mouscadel V, Puchois V, Blein S, Bedos J-P, Diehl J-L, Hamzaoui O, Annane D, et al. Circulating biomarkers may be unable to detect infection at the early phase of sepsis in ICU patients: the CAPTAIN prospective multicenter cohort study. *Intensive Care Med* 2018;44:1061–70.

23 Qiao Z, Wang W, Yin L, Luo P, Greven I, Horst K, Hildebrand F. Using IL-6 concentrations in the first 24 h following trauma to predict immunological complications and mortality in trauma patients: a meta-analysis. *Eur J Trauma Emerg Surg* 2014;44:679–87.

24 Khan S, Brohi K, Chana M, Raza J, Stanworth S, Gaarder C, Davenport R, International Trauma Research Network (INTRN). Hemostatic resuscitation is neither hemostatic nor resuscitative in trauma hemorrhage. *J Trauma Acute Care Surg* 2014;76:561–8. discussion 7–8.

25 Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Calidwell E, Fan E, Camporota S, Slutsky AS, ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. *JAMA* 2012;307:2526–33.

26 Bingold TM, Lefering R, Zacharowski K, Meybohm P, Waydhas C, Rosenberger P, Scheller B, DIVI Intensive Care Registry Group. Individual organ failure and concomitant risk of mortality differs according to the type of admission to ICU – a retrospective study of SOFA score of 23,795 patients. *PloS One* 2015;10:e0134339.

27 Fröhlich M, Wafaisade A, Mansuri A, Koenen P, Protob C, Mægele M, Bouillon B, Sakka SG. Which score should be used for posttraumatic multiple organ failure? - Comparison of the MODS, Denver- and SOFA-Scores. *Scand J Trauma Resusc Emerg Med* 2016;24:130.

28 Bellomo R, Ronco C, Kellum JA, Mehta R, Palevsky P. Acute Dialysis Quality Initiative writing group: Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2004;8:R204–12.

29 Gomes E, Antunes R, Dias C, Araújo R, Costa-Pereira A. Acute kidney injury in severe trauma assessed by rifle criteria: a common feature without implications on mortality. *Scand J Trauma Resusc Emerg Med* 2016;24:130.

30 Schrijver IT, Kemperman H, Roest M, Kesecioglu J, de Lange DW. Myeloperoxidase concentrations in the first 24 h following trauma to predict immunological complications and mortality in trauma patients: a meta-analysis. *Eur J Trauma Emerg Surg* 2018;44:679–87.

31 Huber-Lang M, Lambris JD, Ward PA. Innate immune responses to trauma. *Nat Immunol* 2018;19:327–41.

32 Wood MD, Beresford NA, Copplestone D. Limit of detection values in data analysis: do they matter? *Radioprotection* 2011;46:585–90.

33 Peduzzi P, Concasto J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. *J Clin Epidemiol* 1996;49:1373–9.

34 Balvers K, Curry N, Kleinveld DJB, Böing AN, Nieuwland R, Goslings JC, Juffermans NP. Endogenous microparticles drive the proinflammatory host immune response in severely injured trauma patients. *Shock* 2015;43:317–21.

35 Heftrig D, Sturm R, Oppermann E, Konradtzick V, Jurida K, Schimunek M, Marzi I, Relja B. Impaired surface expression of HLA-DR, TL2, TL4, and TL9 in ex vivo-in vitro stimulated monocytes from severely injured trauma patients. *Mediators Inflamm* 2017;2017:1–12.

36 Timmermans K, Kox M, Vaneker M, van den Berg M, John A, van Laarhoven A, van der Hoeven H, Scheffer GJ, Pickkers P. Plasma levels of danger-associated-molecular patterns are associated with immune suppression in trauma patients. *Intensive Care Med* 2016;42:551–61.

37 Hazeldine J, Dinsdale RJ, Harrison P, Lord JM. Traumatic injury and exposure to mitochondrial-derived damage associated molecular patterns suppress neutrophil extracellular trap formation. *Front Immunol* 2019;10.

38 Sun M, Brady RD, Wright DK, Kim HA, Zhang X, Soobey CG, Johnstone MR, O’Brien TJ, Semple BD, McDonald SJ, et al. Treatment with an interleukin-1 receptor antagonist mitigates neuroinflammation and brain damage after polytrauma. *Brain Behav Immun* 2017;66:359–71.

39 Lin J, Zhang W, Wang L, Tian F. Diagnostic and prognostic values of Club cell protein 16 (CC16) in critical care patients with acute respiratory distress syndrome. *J Clin Lab Anal* 2018;32:e22262.

40 Störmann P, Becker N, Vollrath JT, Köhler K, Janicova A, Wutzler S, Hildebrand F, Marzi I, Relja B. Early local inhibition of Club cell protein 16 following chest trauma reduces late sepsis-induced acute lung injury. *JCM* 2019;8:896.

41 Sousa A, Raposo F, Fonseca S, Valente L, Duarte F, Gonçalves M, Tuna D, Paiva J-A. Measurement of cytokines and adhesion molecules in the first 72 hours after severe trauma: association with severity and outcome. *Dis Markers* 2015;2015:1–8.

42 Partrick DA, Moore FA, Moore EE, Biffl WL, Sauaia A, C.Barnett C, The American Journal of Surgery 1996;172:425–31.

43 Miyamoto K, Shibata N, Ogawa A, Nakashima T, Kato S. Plasma levels of danger-associated-molecular patterns are associated with immune suppression in trauma patients. *Intensive Care Med* 2019;45:1245–56.